Introduction
Infection with multidrug-resistant Escherichia coli is a challenging public health issue which creates increasing difficulty in the diagnosis and therapeutic options. [1, 2, 3] Evolution of resistance to β-lactam antibiotics in gram negative pathogens, particularly in E. coli commonly results in the production of extended-spectrum beta-lactamases (ESBLs) which confer resistance to expanded spectrum cephalosporins and monobactam. [2, 4] Plasmid encoded bla SHV represent a significant subgroup of Class A β-lactamases in which most of them are found in members of enterobacteriaceae vol. 34, No. 1 www.ijmm.org screening followed by confirmation by combined disc diffusion method as per CLSI guidelines. [8] 
Molecular characterisation and sequencing
Polymerase chain reaction (PCR) was carried out for molecular characterisation and detection of bla ESBL genes. A set of three primers were used: bla TEM , bla CTX-M and bla SHV primers [9] under the following reaction conditions: Initial denaturation 95°C for 2 min, 34 cycles of 95°C for 20 s, 54°C for 1 min, 72°C for 1 min and final extension at 72°C for 7 min. Amplified PCR products were purified by Gene Jet PCR purification Kit (Thermo scientific, Lithuania). 25 µl of purified PCR products were used for sequencing along with ESBL gene primers. A previously confirmed isolate of E. coli harbour SHV obtained from the Department of Microbiology, IMS, BHU, Varanasi, was used as positive control for molecular characterisation. [10] The amplified product was sequenced, and sequencing result was compared by NCBI BLAST search.
Detection of genetic environment of extended-spectrum beta-lactamase genes
Integrase gene PCR was carried out for characterisation of Class 1 and Class 2 integron in all isolates using primers as described previously. [11] The location of SHV genes within integron was determined by amplification of whole cassette 5CS and 3CS primers. [11] All the purified PCR products were cloned on the pGEM-T vector (Promega, Madison, USA) and sequenced. The nucleotide sequences were analysed by using the software available on the National Centre of Biotechnology Information website (http://www.ncbi. nlm.nih.gov). Further linkage of IS26 with SHV gene was determined by PCR with following reaction conditions: Initial denaturation 95°C for 2 min, 35 cycles of 95°C for 20 s, 50°C for 45 s, 72°C for 2 min and final extension at 72°C for 7 min. The primer which was used in the study is described earlier. [12] Plasmid preparation, transferability, incompatibility group typing and stability assay
Bacterial isolates were grown overnight in Luria Bertani (LB) broth (Hi-Media, Mumbai, India) containing 0.5 µg/ml of cefotaxime and plasmids were extracted using the QIAGEN ® Plasmid Mini Kit (Germany). The transformation was carried out using E. coli JM107 as recipient and selected on LB agar plates containing cefotaxime 0.5 µg/ml. Conjugation experiments were performed between the clinical isolates and streptomycin resistant E. coli strain B, as the recipient (Genei, Banglore). Incompatibility groups were determined by PCR-based replicon typing, targeting 18 different replicon types among all the transformants and transconjugants carrying bla SHV gene. [13] Plasmid fitness analysis of all bla SHV-148 producers as well as their transformants and transconjugants were analysed by serial passages method for 110 consecutive days at 1:1000 dilutions in LB broth without antibiotic pressure as described previously. [14] PCR assay was carried out for the presence of bla SHV in the isolates after each passage.
Strain typing
Genotyping of all the bla SHV harbouring E. coli isolates were performed by digestion of agarose plugs with XbaI and analysed by pulsed field gel electrophoresis (CHEF DRIII system, BIO-RAD, USA).
Susceptibility testing
Antimicrobial susceptibility of bla SHV harbouring isolates, transformants and transconjugants were determined by Kirby Bauer disc diffusion method. [15] Following antibiotics were used: Amikacin (30 µg), ciprofloxacin (30 µg), gentamicin (10 µg), tigecycline (15 µg), trimithoprim/sulphamethoxazole (1.25/23.75 µg), cefoxitin (30 µg), cefopodoxime (10 µg), ceftriaxone (30 µg), cefepime (30 µg), imipenem (10 µg), meropenem (10 µg), and aztreonam (30 µg) (Hi-Media, Mumbai, India). MIC's of donor strains and transformants as well as transconjugants with cefotaxime, ceftazidime, ceftriazone, cefepime, imipenem, meropenem, ertapenem and aztreonam (Hi-Media, Mumbai, India) were also determined. [8] 
Results
All 33 isolates of E. coli were obtained from urine, pus, oral swabs, drain tip, sputum and stool collected from adult patients (20 to 60 years) in surgery, medicine, female burn unit, paediatrics, medicine, gynaecology and orthopaedics wards/clinics [ Table 1 ]. Of these E. coli isolates, 71 strains (58.67%) were found resistant to expanded spectrum cephalosporins and were phenotypically ESBL positive. These 43 strains showed amplification with the target primers of which 33 were confirmed to be SHV-148 variant by sequencing [ Table 1 ]. All these SHV-148 harbouring strains were carrying Class 1 integron, and the SHV-148 gene was located within integron gene cassette. bla SHV-148 was associated with IS26 and was present in the upstream portion of the gene cassette which was further confirmed by sequencing. Transformation and conjugation result could establish the fact that bla SHV-148 was horizontally transferable and was carried within IncF group of plasmids. The gene was quite stable in the wild type which retained the gene till 91 consecutive passages. Tigecycline was found to be most effective against the isolates. Donor strain, transformants as well as transconjugants, showed high MIC 50 and MIC 90 against all tested cephalosporins but were found below the break point against ertapenem and meropenem [ Tables 2 and 3 ]. Typing results revealed that twenty-seven different clones were distributed in different wards and clinics of this hospital setting. 
Discussion
The prevalence rate of ESBL producing E. coli strains in clinical settings differs considerably over time and geographic location although it is a global problem. In our study 58.67% isolates were found to be ESBL positive, however in another report the authors reported a prevalence rate of 78% in India. [16] In our study, it was observed that an SHV-148 was associated with 5'-end of a Class 1 integron which may help in the mobilisation of this resistant determinant in the hospital environment. In the current study, it was also found that IS26 underlining the most important role in the mobilisation and expression of this gene. Transferability results of our study supported that SHV gene was horizontally transferable in this hospital settings between different wards/clinics. The transferability of bla SHV too has been reported earlier. [2] In our study bla was found to be stable till 91 passages and the IncF group plasmid is likely to be the genetic tool for the dissemination of this resistant gene in our hospital. This was also supported by the typing results. This study further advocates that tigecycline could be used as treatment option considering the development of resistance against carbapenem drug.
Conclusion
Thus this study, to the best of our knowledge, is the first report of SHV-148 mediated extended spectrum cephalosporin resistance from India. Presence of insertion sequence IS26 upstream of SHV-148 advocates its significant role in the mobilisation of bla SHV-148 and also emphasises emergence of this resistance genes from this part of the world, which may be tracked to implement proper infection control policy.
Financial support and sponsorship
University Grants Commissions (UGC-MRP) Government of India and Department of Biotechnology (DBT-NER twinning Scheme and Assam University Biotech Hub).
Conflicts of interest
There are no conflicts of interest. 
